A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
Not yet recruitingOBSERVATIONAL
Enrollment
200
Participants
Timeline
Start Date
November 30, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
June 30, 2027
Conditions
IgA Nephropathy (IgAN)Early Initial Therapy
Interventions
OTHER
Gd-IgA1 test
collect and test Gd-IgA1 test in enrolled subjects
All Listed Sponsors
lead
Sichuan Provincial People's Hospital
OTHER
NCT06676007 - A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy | Biotech Hunter | Biotech Hunter